> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 8 Observations in Dr. Reddy’s FDA-483
- URL: https://www.fdaweb.com/8-observations-in-dr-reddys-fda-483/
- Published: 2021-12-08T12:00:00.000Z
- Updated: 2026-09-14T17:25:04.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150721

FDA has released the FDA-483 issued following a 10/10-10/29 inspection at the Dr. Reddy’s sterile drug manufacturing facility in Duvvada, Andhra Pradesh, India. The eight inspection [observations](https://www.fda.gov/media/154632/download?ref=fdaweb.com) were: 

- the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed;
- laboratory controls do not include the establishment of scientifically sound and appropriate specifications, sampling plans, and test procedures designed to assure that components, in-process materials, and drug products conform to appropriate standards of identity, strength, quality, and purity;
- aseptic processing areas are deficient regarding the system for monitoring environmental conditions;
- procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process;
- establishment of the reliability of the component supplier’s report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals;
- the accuracy, specificity, and reproducibility of test methods have not been established and documented;
- there is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed; and
- the control systems necessary to prevent contamination or mix-ups are deficient.